S100A8 and angina pectoris: Accordingly, this clinical evidence supports that S100A8/A9 is a feasible biomarker to distinguish patients with ACS from those with stable angina and that elevated circulating S100A8/A9 is clinically relevant to long-term adverse prognosis (Table 1).